1. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de YG, Zucali R, Rilke F:Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539?1545, 1990
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, De Cillis A, Robidoux A, Margolese RG, Cruz AB, Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672?2685, 1998
3. Miller WR, Anderson TJ, Hawkins RA, Keen J, Dixon JM:Neoadjuvant endocrine treatment:the Edin-burgh experience. In:Howell A, Dowsett M (eds), Primary medical therapy for breast cancer:clinical and biological aspects. Amsterdam: Elsevier Science BV:89?99, 1999
4. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M:Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase III randomized trial. J Clin Oncol 19:3808?3816, 2001
5. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M:Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentauoropentylsul nyl)-nonyl ]estra-1, 3, 5, (10)-triene-3, 17betadiol (Faslodex)versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739?6746, 2001